MLTX - CIK 0001821586
The table below shows MoonLake Immunotherapeutics's cash flow statement line items across its last 5 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$196.01M | -$116.59M | -$42.78M | -$55.89M | -$611.07K |
| Capital expenditure | $35.00K | $520.00K | $284.00K | $16.01K | - |
| Investing cash flow | $202.99M | -$205.60M | -$25.18M | -$32.34M | - |
| Dividends paid | - | - | - | - | - |
| Stock buybacks | - | $50.00 | $0.00 |
MoonLake Immunotherapeutics reported operating cash flow of -$196.01M for fiscal year 2025. That is down 68.1% from -$116.59M in fiscal 2024. Over the 5 fiscal years shown, operating cash flow declined from -$611.07K (FY 2021) to -$196.01M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $0.00 |
| - |
| Financing cash flow | $146.00M | $51.31M | $479.70M | $119.69M | -$58.06K |